NRXN1 and neoplasm: Moreover, Yotsumoto et al. identified NRXN1 as a tumor-specific marker and reported that when it is overexpressed on the cell surface, it is a novel molecular target for the development of effective antibody drug conjugates (ADCs) against small-cell lung cancer [17].